





0001/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		Application Number 10/660,434
TRANSMITTAL FORM <i>(to be used for all correspondence during pendency of filed application)</i>				Filing Date September 10, 2003
				First Named Inventor Guennadi V. Glinskii
				Group Art Unit Number Not yet known - 1651
				Examiner Name Not yet known
				Total Number of Pages in This Submission 7*

ENCLOSURES (check all that apply)	
<input type="checkbox"/> Fee Transmittal Form (in duplicate)	<input type="checkbox"/> Issue Fee Transmittal
<input type="checkbox"/> Check Enclosed	<input type="checkbox"/> Letter to Chief Draftsperson
<input checked="" type="checkbox"/> Return Receipt Postcard	<input type="checkbox"/> Formal Drawing(s):
<input type="checkbox"/> Response to Notice to File Missing Parts	<input type="checkbox"/> [] Sheet(s) of Figure(s) []
<input type="checkbox"/> Assignment & Recordation Cover Sheet	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Declaration	<input type="checkbox"/> Appeal Communication to Group
<input type="checkbox"/> Power of Attorney	<input type="checkbox"/> (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Application Data Sheet	<input type="checkbox"/> Certified Copy of Priority Document(s)
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement & PTO/SB/08A	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Copies of IDS Cited References	<input type="checkbox"/>
<input type="checkbox"/> Request for Corrected Filing Receipt	<input type="checkbox"/>
<input type="checkbox"/> Request for Correction of Recorded Assignment	<input type="checkbox"/>
<input type="checkbox"/> Amendment/Response: [] Page(s)	<input type="checkbox"/>
<input type="checkbox"/> After Final	<input type="checkbox"/>
<input type="checkbox"/> Status Request	<input type="checkbox"/>
<input type="checkbox"/> Revocation and Substitute Power of Attorney	<input type="checkbox"/>
REMARKS: *Page count does not reflect cited references.	

SIGNATURE OF ATTORNEY OR AGENT			
Signature:			
Attorney/Reg. No.:	Susan T. Hubl, Patent Agent, Reg. No. 47,668	Dated:	Dec. 22, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. If the Express Mail Mailing Number is filled in below, then this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service pursuant to 37 CFR 1.10.			
Signature:			
Typed or Printed Name:		Susan T. Hubl	Dated: Dec. 22, 2003
Express Mail Mailing Number (optional):			



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Guennadi V. Glinskii
APPLICATION NO.: 10/660,434
FILING DATE: September 10, 2003
TITLE: Gene Segregation And Biological Sample Classification Methods
EXAMINER: Not yet known
GROUP ART UNIT: ~~Not yet known~~ 1651
ATTY. DKT. NO.: 23543-07570

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated: Dec. 22

, 2003

By:

Susan T. Hubl, Patent Agent, Reg. No.: 47,668

MAIL STOP NON-FEE AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;

- ☐ before the mailing of a first official action after the filing of a request for continued examination (RCE) under 37 CFR § 1.114;
- ☐ after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before the mailing date of the first to occur of either: (1) a final action under 37 CFR § 1.113; or (2) an action that otherwise closes prosecution in the application, and:
 - ☐ attached hereto is the fee set forth under 37 CFR § 1.17(p) for submission of this Information Disclosure Statement under 37 CFR § 1.97(c); OR
 - ☐ Applicant certifies pursuant to 37 CFR § 1.97(e) that:
 - ☐ each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; OR
 - ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement;
- ☐ on or before the payment of the issue fee but after the mailing date of the first to occur of either: (1) a final action under 37 CFR § 1.113; (2) a notice of allowance under 37 CFR § 1.311; or (3) an action that otherwise closes prosecution in the application, and:
 - ☐ Applicant certifies pursuant to 37 CFR § 1.97(e) that:
 - ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
 - ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a


foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement; AND


- ☐ attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR. § 1.97(c); OR
- ☐ after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 CFR § 1.97(i), although the information may not be considered by the USPTO.
- ☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. APPLICATION NO., filed on DATE FILED, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).
- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 CFR § 1.704(d).
- ☒ Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
Guennadi V. Glinskii

Dated: 12/22/03

By: 
Susan T. Hubl, Patent Agent, Reg. No.: 47,668
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (415) 875-2316
Fax.: (415) 395-0879



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***Submitted 12/22/03***Complete if Known**

Application N .	10/660,434
Filing Date	September 10, 2003
First Named Inventor	Guennadi V. Glinskii
Art Unit	Not yet known 1651
Examiner Name	Not yet known
Attorney Docket Number	23543-07570

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number - Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1 21	BHATTACHARJEE, ARINDAM, et al.; Classification Of Human Lung Carcinomas By mRNA Expression Profiling Reveals Distinct Adenocarcinoma Subclasses; Proc. Natl. Acad. Sci.; November 20, 2001; pp. 13790-13795; vol. 98, no. 24.	
	C2 22	BUCKHAULTS, PHILLIP, et al.; Secreted And Cell Surface Genes Expressed In Benign And Malignant Colorectal Tumors; Cancer Research; October 1, 2001; pp. 6996-7001; vol. 61.	
	C3 23	FUJII, TAKESHI, et al.; A Preliminary Transcriptome Map Of Non-Small Cell Lung Cancer; Cancer Research; June 15, 2002; pp. 3340-3346; vol. 62.	
	C4 24	GIORDANO, THOMAS J., et al.; Short Communication: Organ-Specific Molecular Classification Of Primary Lung, Colon, And Ovarian Adenocarcinomas Using Gene Expression Profiles; American Journal of Pathology; October 2001; pp. 1231-1238; vol. 159, no. 4.	
	C5 25	GLINSKII, G.V., et al.; Microarray Gene Expression Analysis Of Tumor Progression In The Nude Mouse Model Of Human Prostate Cancer; In Proceedings of the 93 rd Annual Meeting for the American Association for Cancer Research; Abstract #4480; April 6-10, 2002; 43: 462.	
	C6 26	GORDON, GAVIN J., et al.; Translation Of Microarray Data Into Clinically Relevant Cancer Diagnostic Tests Using Gene Expression Ratios In Lung Cancer And Mesothelioma; Cancer Research; September 1, 2002; pp. 4963-4967; vol. 62.	
	C7 27	LATULIPPE, EVA, et al.; Comprehensive Gene Expression Analysis Of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease; Cancer Research; August 1, 2002; pp. 4499-4506; vol. 62.	
	C8 28	MONNI, OUTI, et al.; Comprehensive Copy Number And Gene Expression Profiling Of The 17q23 Amplicon In Human	


Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1399816.1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

submitted 12/22/03

Complete if Known

Application No.	10/660,434
Filing Date	September 10, 2003
First Named Inventor	Guennadi V. Glinskii
Art Unit	Not yet known - 1651
Examiner Name	Not yet known
Attorney Docket Number	23543-07570

Sheet 2 of 2

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Breast Cancer; Proc. Natl. Acad. Sci.; May 8, 2001; pp. 5711-5716; vol. 98, no. 10.	
	C8 29	MOUSSES, SPYRO, et al.; Clinical Validation Of Candidate Genes Associated With Prostate Cancer Progression In The CWR22 Model System Using Tissue Microarrays; Cancer Research; March 1, 2002; pp. 1256-1260; vol. 62.	
	C18 30	NARLA, GOUTHAM, et al., KLF6, A Candidate Tumor Suppressor Gene Mutated In Prostate Cancer; Science; December 21, 2001; pp. 2563-2566; vol. 294.	
	C11 31	RAMASWAMY, SRIDHAR, et al.; DNA Microarrays In Clinical Oncology; Journal of Clinical Oncology; April 1, 2002; pp. 1932-1941; vol. 20, no. 7.	
	C12 32	SAVERIO, BETTUZZI, et al.; Tumor Progression Is Accompanied By Significant Changes In The Levels Of Expression Of Polyamine Metabolism Regulatory Genes And Clusterin (Sulfated Glycoprotein 2) In Human Prostate Cancer Specimens; Cancer Research; January 1, 2000; pp. 28-34; vol. 60.	
	C18 33	SHOU, JIANYONG; et al.; Expression Profiling Of A Human Cell Line Model Of Prostatic Cancer Reveals A Direct Involvement Of Interferon Signaling In Prostate Tumor Progression; Proc. Natl. Acad. Sci.; March 5, 2002; pp. 2830-2835; vol. 99, no. 5.	
	C14 34	SU, ANDREW I.; et al.; Large-scale Analysis Of The Human And Mouse Transcriptomes; Proc. Natl. Acad. Sci.; April 2, 2002; pp. 4465-4470; vol. 99, no. 7.	
	C18 35	SUGITA, MICHIO, et al.; Combined Use Of Oligonucleotide And Tissue Microarrays Identifies Cancer/Testis Antigens As Biomarkers In Lung Carcinoma; Cancer Research; July 15, 2002; pp. 3971-3979; vol. 62.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.